Rucaparib
Last Updated: 04/28/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 682 publications
MOB2 Loss Sensitizes Lung Cancer Cells to PARP Inhibition Through p53-Dependent DNA Damage Signaling.
Journal: Current issues in molecular biology
Published: February 14, 2026
Targeting VEGF, PARP, and FRα Pathways in Ovarian Cancer: Clinical Advances with Bevacizumab, Rucaparib, and Mirvetuximab Soravtansine.
Journal: Journal of clinical medicine
Published: January 25, 2026
Novel Immunotherapeutic Strategies for Castration-Resistant Prostate Cancer: Mechanisms and Clinical Advances.
Journal: Current issues in molecular biology
Published: January 23, 2026
Emerging Therapeutic Synergies: Combining PD-1 Inhibitors With Poly-ADP-Ribose Polymerase (PARP) Inhibitors in the Treatment of Gynecologic Cancers.
Journal: Cureus
Published: December 14, 2025
Rucaparib in refractory pleural mesothelioma harboring somatic pathogenic BRCA1 and BRCA2 mutation. A report of two cases.
Journal: Lung cancer management
Published: December 12, 2025
Poly (ADP-ribose) polymerase (PARP) inhibitors approved for the treatment of cancer.
Journal: Pharmacological research
Published: December 01, 2025
Global Proteomic Determination of the Poly-Pharmacological Effects of PARP Inhibitors Following Treatment of High-Grade Serous Ovarian Cancer Cells.
Journal: International journal of molecular sciences
Published: November 03, 2025
Development of Mitochondria-Targeted PARP Inhibitors.
Journal: Biomolecules
Published: October 29, 2025
BrUOG360: A Phase Ib/II Study of Copanlisib in Combination with Rucaparib in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC).
Journal: Cancer research communications
Published: October 21, 2025
Receipt of PARP Inhibitors in Patients With Metastatic Prostate Cancer Harboring BRCA1/2 Alterations.
Journal: JAMA network open
Published: October 02, 2025
Last Updated: 04/28/2026